Table 2.
Survival predictors: Univariate Cox regression analysis
| Predictor | HR | 95%CI of HR |
P |
|---|---|---|---|
| Age (>60 vs ≤60) | 0.88 | 0.66-1.16 | 0.351 |
| Gender (male vs female) | 1.44 | 1.06-1.96 | 0.018 |
| Race (white vs nonwhite) | 0.75 | 0.56-1.00 | 0.051 |
| Hepatitis Virus infection | |||
| (no infection vs HBV+HCV) | 0.51 | 0.32-0.80 | 0.004 |
| (HBV alone vs HBV+HCV) | 0.76 | 0.44-1.32 | 0.334 |
| (HCV alone vs HBV+HCV) | 0.72 | 0.43-1.18 | 0.192 |
| AFP (≥400 vs <400) | 2.26 | 1.69-3.02 | <0.0001 |
| Tumor differential (poor vs other) | 1.63 | 1.15-2.31 | 0.006 |
| Tumor nodularity (multi vs uni) | 2.28 | 1.68-3.11 | <0.0001 |
| Tumor size (>50% vs ≤50%) | 2.92 | 2.19-3.90 | <0.0001 |
| Vascular invasive (yes vs no) | 2.65 | 1.90-3.70 | <0.0001 |
| Lymph Node involvement (yes vs no) | 1.82 | 1.38-2.40 | <0.0001 |
| Metastasis (yes vs no) | 1.76 | 1.27-2.45 | 0.001 |
| Bilirubin (>1.6 vs ≤1.6) | 2.74 | 1.78-4.22 | <0.0001 |
| Serum ALT (>40 vs ≤40) | 1.77 | 1.34-2.34 | <0.0001 |
| Serum AST (>45 vs ≤45) | 2.17 | 1.57-3.00 | <0.0001 |
| Cirrhosis (yes vs no) | 1.35 | 1.02-1.79 | 0.036 |
| Treatment (chemotherapy vs none) | 0.56 | 0.38-0.84 | 0.0047 |
| (surgery vs none) | 0.19 | 0.12-0.31 | <.0001 |
| (chemoembolization vs none) | 0.38 | 0.22-0.67 | 0.0008 |
| VEGF (100-unit increase) | 1.04 | 1.01-1.07 | 0.007 |